Silence Therapeutics Notice of Results

Silence Therapeutics Notice of Results

1 September 2020

LONDON, Silence Therapeutics plc (LON: SLN) ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, will announce its unaudited interim results for the half year ended 30 June 2020, on 14 September 2020.

Iain Ross, Executive Chairman, Dr. Rob Quinn, Chief Financial Officer and Dr. Giles Campion, Head of R&D and Chief Medical Officer will host a webcast and live conference call for analysts and investors at 13:00 BST | 08:00 ET on the day of the results.

Details of the webcast and conference call:

Webcast link: https://edge.media-server.com/mmc/p/8yn44oft

Dial-in Details:

United Kingdom 08002796619

United States 18778709135

Conference ID 7577462

For more information, please contact:

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/